Sujit Itty1, Shelley Day, Kenneth W Lyles, Sandra S Stinnett, Lejla M Vajzovic, Prithvi Mruthyunjaya. 1. *Department of Ophthalmology, Duke University Medical Center; †Department of Ophthalmology, Stanford Medical Center; ‡Department of Medicine, Duke University Medical Center; §Geriatric Research Education and Clinical Centers, Veterans Affairs Medical Center, Durham, North Carolina; ¶The Carolinas Center for Medical Excellence, Cary, North Carolina; and **Division of Biostatistics, Duke University Medical Center.
Abstract
PURPOSE: To compare 25-hydroxyvitamin D (25OHD) levels in patients with neovascular age-related macular degeneration (NVAMD) with patients with nonneovascular age-related macular degeneration and control patients. METHODS: Medical records of all patients diagnosed with age-related macular degeneration and tested for serum 25OHD level at a single medical center were reviewed. Control patients were selected from patients diagnosed with pseudophakia but without age-related macular degeneration. The lowest 25OHD level available for each patient was recorded. RESULTS: Two hundred sixteen patients with nonneovascular age-related macular degeneration, 146 with NVAMD, and 100 non-age-related macular degeneration control patients were included. The levels of 25OHD (mean ± SD) were significantly lower in NVAMD patients (26.1 ± 14.4 ng/mL) versus nonneovascular age-related macular degeneration (31.5 ± 18.2 ng/mL, P = 0.003) and control (29.4 ± 10.1 ng/mL, P = 0.049) patients. The prevalence of vitamin D insufficiency (<30 ng/mL 25OHD), deficiency (<20 ng/mL), and severe deficiency (<10 ng/mL) were highest in the NVAMD group. The highest quintile of 25OHD was associated with a 0.35 (95% confidence interval, 0.18-0.68) odds ratio for NVAMD. CONCLUSION: This is the largest study to compare 25OHD levels in patients with the different clinical forms of age-related macular degeneration. Mean 25OHD levels were lower and vitamin D deficiency was more prevalent in NVAMD patients. These associations suggest that further research is necessary regarding vitamin D deficiency as a potentially modifiable risk factor for the development of NVAMD.
PURPOSE: To compare 25-hydroxyvitamin D (25OHD) levels in patients with neovascular age-related macular degeneration (NVAMD) with patients with nonneovascular age-related macular degeneration and control patients. METHODS: Medical records of all patients diagnosed with age-related macular degeneration and tested for serum 25OHD level at a single medical center were reviewed. Control patients were selected from patients diagnosed with pseudophakia but without age-related macular degeneration. The lowest 25OHD level available for each patient was recorded. RESULTS: Two hundred sixteen patients with nonneovascular age-related macular degeneration, 146 with NVAMD, and 100 non-age-related macular degeneration control patients were included. The levels of 25OHD (mean ± SD) were significantly lower in NVAMD patients (26.1 ± 14.4 ng/mL) versus nonneovascular age-related macular degeneration (31.5 ± 18.2 ng/mL, P = 0.003) and control (29.4 ± 10.1 ng/mL, P = 0.049) patients. The prevalence of vitamin Dinsufficiency (<30 ng/mL 25OHD), deficiency (<20 ng/mL), and severe deficiency (<10 ng/mL) were highest in the NVAMD group. The highest quintile of 25OHD was associated with a 0.35 (95% confidence interval, 0.18-0.68) odds ratio for NVAMD. CONCLUSION: This is the largest study to compare 25OHD levels in patients with the different clinical forms of age-related macular degeneration. Mean 25OHD levels were lower and vitamin D deficiency was more prevalent in NVAMD patients. These associations suggest that further research is necessary regarding vitamin D deficiency as a potentially modifiable risk factor for the development of NVAMD.
Authors: Anthony J Perkins; Kurt Kroenke; Jürgen Unützer; Wayne Katon; John W Williams; Carol Hope; Christopher M Callahan Journal: J Clin Epidemiol Date: 2004-10 Impact factor: 6.437
Authors: Dominiek D G Despriet; Caroline C W Klaver; Jacqueline C M Witteman; Arthur A B Bergen; Isabella Kardys; Moniek P M de Maat; Sharmila S Boekhoorn; Johannes R Vingerling; Albert Hofman; Ben A Oostra; André G Uitterlinden; Theo Stijnen; Cornelia M van Duijn; Paulus T V M de Jong Journal: JAMA Date: 2006-07-19 Impact factor: 56.272
Authors: Daniel M Albert; Elizabeth A Scheef; Shoujian Wang; Farideh Mehraein; Soesiawati R Darjatmoko; Christine M Sorenson; Nader Sheibani Journal: Invest Ophthalmol Vis Sci Date: 2007-05 Impact factor: 4.799
Authors: A E Millen; J Nie; M W Sahli; J A Mares; K J Meyers; B E K Klein; M J LaMonte; P L Lutsey; C A Andrews; R Klein Journal: J Nutr Health Aging Date: 2017 Impact factor: 4.075
Authors: Alfredo Garcia Layana; Angelo Maria Minnella; Gerhard Garhöfer; Tariq Aslam; Frank G Holz; Anita Leys; Rufino Silva; Cécile Delcourt; Eric Souied; Johanna M Seddon Journal: Nutrients Date: 2017-10-13 Impact factor: 5.717